InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia — Stella

Home/Shigellosis/

View on ClinicalTrials.gov

Recruiting

Back to Shigellosis trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Netherlands

Leiden University Medical Center, Leiden

Key details

Phase

Early testing

Sponsor

Leiden University Medical Center

Collaborators

Centre for Infectious Disease Research in Zambia, PATH

Enrollment target

~85 participants

Started

October 2024

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 50 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.